Dyno Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Dyno Therapeutics, Inc.
Astellas inks agreement with Dyno Therapeutics for access to its CapsidMap platform for novel AAV vectors. Taiho takes option to Arcus TIGIT-targeted antibody candidates.
Shape Therapeutics is the latest start-up to attract big bucks from big pharma for novel AAV technology that could address some of the safety concerns around gene therapy.
Several companies have recently raised large amounts of money from venture capital as well as potentially through partnerships for next-generation capsid technology.
Biogen is Capsigen’s first partner, while Dyno Therapeutics has also entered into deals potentially worth billions with large drug and biotech firms.
- Artificial Intelligence
- Gene Therapy, Cell Therapy
Drug Discovery Tools